Skip to main content
Equibles
TRDA logo

TRDA · Entrada Therapeutics, Inc. · Metrics

Track TRDA — free

Use TRDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.80 +0.38 (+5.92%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$248.42M
Shares
38.94M

TRDA metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.80
Market cap
$248.42M

Price action

20 metrics
Price change (1W)
-10.5%
Price change (30D)
-13.8%
Price change (3M)
+1.7%
Price change (6M)
-50.5%
Price change (YTD)
-37.5%
Price change (1Y)
+23.0%
Trailing year
Price change (5Y)
—
52-week high
$16.03
52-week low
$5.06
Change from 52-week high
-60.0%
Change from 52-week low
+26.9%
Annualized volatility
86.3%
Annualized volatility (3M)
68.3%
Beta
1.6
RSI (14D)
39.5
Price vs SMA 50
-8.7%
Price vs SMA 200
-33.4%
Avg volume (3M)
363,573
Relative volume
1.2
Average dollar volume
$2.55M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
38.94M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
53.0×
reciprocal yield 1.9%
P / book
1.1
reciprocal yield 94.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-66.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-07

Profitability

9 metrics
Gross margin
—
Operating margin
-3,767.1%
Trailing 12 months
Net margin
-3,537.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$176.53M
Net income (TTM)
−$165.78M
Trailing 12 months
Diluted EPS (TTM)
$-3.97
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.00

Growth

11 metrics
Revenue growth YoY
-53.9%
Year over year
Net income growth YoY
-319.0%
Revenue (TTM)
$4.69M
Trailing 12 months
EPS growth YoY
-306.5%
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-71.0%
Return on assets
-55.5%
Debt / equity
—
Current ratio
10.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
10.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$99.28M
Total assets
$298.88M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$134.67M
Capital expenditures (TTM)
—
R&D (TTM)
$140.74M
SG&A (TTM)
—
Stock compensation (TTM)
$19.37M
R&D / revenue
3,003.4%
Stock compensation / revenue
413.3%

Ownership (13F)

3 metrics
13F filers
128
13F filer change QoQ
+9
Institutional ownership
74.7%

Short interest

3 metrics
Short interest
6.0%
Latest settlement · 10.7 days to cover
Days to cover
10.7d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$10.33M
Insider-sentiment score
7 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1689375 CUSIP 29384C108 13F (30d) 75 filings 75 filers Visit website Investor relations